Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Finianos, 2018, Characterization of differences between prostate cancer patients presenting with de novo versus primary progressive metastatic disease, Clin Genitourin Cancer, 16, 85, 10.1016/j.clgc.2017.08.006

Patrikidou, 2014, Who dies from prostate cancer?, Prostate Cancer Prostatic Dis, 17, 348, 10.1038/pcan.2014.35

Saad, 2015, Androgen deprivation therapy and secondary hormone therapy in the management of hormone-sensitive and castration-resistant prostate cancer, Urology, 86, 852, 10.1016/j.urology.2015.07.034

Horwich, 2013, Prostate cancer: ESMO Consensus Conference Guidelines 2012, Ann Oncol, 24, 1141, 10.1093/annonc/mds624

Patrikidou, 2015, Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome, Urol Oncol, 33, 202.e9, 10.1016/j.urolonc.2015.01.022

Gravis, 2016, Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial, Eur Urol, 70, 256, 10.1016/j.eururo.2015.11.005

Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial, J Clin Oncol, 36, 1080, 10.1200/JCO.2017.75.3657

James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5

Gravis, 2018, Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies, Eur Urol, 73, 847, 10.1016/j.eururo.2018.02.001

Vale, 2016, Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, Lancet Oncol, 17, 243, 10.1016/S1470-2045(15)00489-1

Gillessen, 2018, Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, Eur Urol, 73, 178, 10.1016/j.eururo.2017.06.002

Mottet, 2018, Updated guidelines for metastatic hormone-sensitive prostate cancer: abiraterone acetate combined with castration is another standard, Eur Urol, 73, 316, 10.1016/j.eururo.2017.09.029

Hamilou, 2017, Treatment of castration-naive metastatic prostate cancer, Eur Urol Focus, 3, 518, 10.1016/j.euf.2018.02.004

Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 16, 152, 10.1016/S1470-2045(14)71205-7

Fizazi, 2012, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 13, 983, 10.1016/S1470-2045(12)70379-0

Taplin, 2014, Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study, J Clin Oncol, 32, 3705, 10.1200/JCO.2013.53.4578

Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174

Chi, 2018, Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial, Lancet Oncol, 19, 194, 10.1016/S1470-2045(17)30911-7

James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900

Rydzewska, 2017, Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis, Eur J Cancer, 84, 88, 10.1016/j.ejca.2017.07.003

Fizazi, 2018, Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial, J Clin Oncol, 36, 5023, 10.1200/JCO.2018.36.15_suppl.5023

Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747

Hoyle, 2018, Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer, Ann Oncol, 29, 10.1093/annonc/mdy424.033

Feyerabend, 2018, Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis, Eur J Cancer, 103, 78, 10.1016/j.ejca.2018.08.010

Vale, 2018, What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis, Ann Oncol, 29, 1249, 10.1093/annonc/mdy071

Wallis, 2018, Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis, Eur Urol, 73, 834, 10.1016/j.eururo.2017.10.002

Sydes, 2018, Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol, Ann Oncol, 29, 1235, 10.1093/annonc/mdy072

Fizazi, 2016, Low incidence of corticosteroid-associated adverse events on long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer, Eur Urol, 70, 438, 10.1016/j.eururo.2016.02.035

Lavaud, 2018, Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-naive prostate cancer in the GETUG-AFU 15 phase 3 trial, Eur Urol, 73, 696, 10.1016/j.eururo.2017.09.022

de Bono, 2017, Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302, Eur Urol, 71, 656, 10.1016/j.eururo.2016.06.033

Al Nakouzi, 2015, Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies, Eur Urol, 68, 228, 10.1016/j.eururo.2014.04.015